PharmaEssentia secures FDA approval for BESREMi in essential thrombocythemia. What did the trial show?
PharmaEssentia has secured FDA approval for BESREMi in adults with essential thrombocythemia after the Phase 3 SURPASS ET trial showed a 37.4% durable response rate versus 3.6% with anagrelide.